Program
cyclobenzaprine
Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.
Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.
Drug pageCyclobenzaprine: every studyMany companies study it; this page follows only the 32 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonix Pharmaceuticalsits history only | 262 open or running | phase 3since Jul 12, 2013 | Dec 7, 2011 | Feb 2028phase 2 · NCT07621237 |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Neurana Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| Takeda | 10 open or running | phase 3since Jun 23, 2016 | Jun 23, 2016 | none ahead |
Also a collaborator on its studies: Altasciences, Premier Research Group and Cognitive Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 23, 2016First study: phase 3 study in Neck PainFirst studyNCT02814565 · 180 enrolled · Russian Federation
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| Trazodonerule | Angelini Pharma | phase 3 | 14 |
Studies
The one study Takeda leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02814565Neck Pain · Russian Federation | 3 | Completed | Feb 10, 2017 | 180 |
How it is read
Names in the registry
- “TNX-102 SL”, 13 entries
- “TNX-102 SL 5.6 mg”, 2 entries
- “Treatment A”, 2 entries
- “Treatment B”, 2 entries
- “TNX-102 SL Tablet”, 1 entry
Codes read as this program: TNX102.
Conditions, from the studies’ own filings
- Fibromyalgia, 8 studies
- Stress Disorders, Post-Traumatic, 7 studies
- Depressive Disorder, Major, 1 study
- Post-Acute COVID-19 Syndrome, 1 study
- Neck Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.